Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regenerating Interest In Novel Drugs For Postmenopausal Osteoporosis

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

New bone-targeted agents for osteoporosis must clear significant obstacles to succeed in a highly generic market, but safety concerns with established agents like bisphosphonates and calcitonin offer a foothold. Phase III anabolic candidates from Amgen and Radius Health aim to build new bone, the holy grail of osteoporosis treatment, but R&D in new anti-resorptive mechanisms to halt bone breakdown also continues.

You may also be interested in...



Amgen/UCB's Phase III Success May Not Be Enough To Top Osteoporosis Rivals

Romosozumab shows ability to reduce risk of spinal fractures, but misses a secondary endpoint on nonvertebral fracture risk reduction.

Merck Moves Forward With Odanacatib Filing; FDA Accepts MK-3475 Filing

At a May 6 investor day, Merck’s R&D head Roger Perlmutter revealed the safety issues that have been delaying the company’s late-stage osteoporosis drug and tried to renew confidence in the treatment.

Beyond Hormone Therapy: Signs Of Life In Pipeline For Menopausal Women

Conditions associated with menopause represent a huge market, yet the R&D pipeline has long been slim, despite the well-known drawbacks of marketed hormone replacement therapies. But new approaches with a tissue-selective estrogenic effect are emerging: Shionogi’s Osphena for menopause-related sexual dysfunction broke the long drought in NME approvals, and Pfizer’s broad NDA for bazedoxifene/conjugated estrogens is under review. Emerging companies like EndoCeutics are exploring new hormonal approaches.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS005372

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel